No prospective trial to date has demonstrated positive outcomes from the administration of phosphodiesterase-5 (PDE-5) inhibitors for the management of PH-ILD, though several trials and related registries suggest a potential benefit. The gene discussed is PDE5A; the disease is interstitial lung disease.